Immunitas Therapeutics

Immunitas Therapeutics, a Waltham, MA-based biotechnology company, develops therapeutics targeting the CD161-CLEC2D pathway for oncology and autoimmune diseases using a single cell genomics-based drug discovery platform. The company has raised $97 million in venture funding, including a $39 million Series A in 2019 and a $58 million Series B in 2021 led by Agent Capital. Its pipeline focuses on NK and T cell modulators, with lead candidate IMT-009 nearing an IND filing in 1H 2022 for solid tumors and hematological cancers. Key leadership includes CEO Amanda Wagner and CSO Thomas Tan; board members include Christoph Westphal, Geeta Vemuri, and Brian Halak. Immunitas Therapeutics was founded in 2019 by Kai Wucherpfennig, K. Dane Wittrup, Mario Suvà, and Aviv Regev. Its business model centers on venture-funded biotechnology company developing clinical-stage therapeutics.

# Immunitas Therapeutics: A Biotech Pioneer, Not a Technology Company

Immunitas Therapeutics is a biotechnology company, not a technology company. While it employs advanced single-cell genomics technology in its drug discovery process, the company's core mission is discovering and developing novel therapeutics for cancer and autoimmune diseases, positioning it squarely within the biopharmaceutical sector rather than the technology industry.

High-Level Overview

Immunitas Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated antibody-based therapeutics targeting the CD161-CLEC2D pathway.[1][3] The company serves patients with cancer and autoimmune diseases by leveraging specialized immunology research to identify and validate novel drug targets. Its lead program, IMT-009 (an anti-CD161 monoclonal antibody), is currently in Phase 1/2a clinical trials for patients with refractory tumors, including microsatellite-stable colorectal cancer, head and neck cancer, and non-small cell lung cancer.[1] The company's approach combines single-cell genomics-based target identification with antibody discovery and engineering, enabling rapid validation of therapeutic candidates in parallel.[2]

Founded in 2019 and headquartered in Waltham, Massachusetts, Immunitas has raised $97 million in total funding across two rounds, with the most recent funding round totaling $58 million.[2] The company operates as a private entity and has not pursued an IPO.

Origin Story

Immunitas was founded by a team of highly renowned cancer researchers and therapeutic antibody pioneers from prestigious institutions including Dana Farber Cancer Institute, Mass General Cancer Center, the Broad Institute, and MIT.[1] This founding team identified CD161 as a compelling T cell target for oncology, recognizing an opportunity to develop therapeutics around a previously underexplored immune checkpoint. The company's scientific foundation reflects deep expertise in immunology and antibody engineering, positioning it to advance novel mechanisms of action in immuno-oncology.

The company's leadership includes Amanda Wagner as CEO and President, Annalisa D'Andrea as Chief Scientific Officer, and James Wooldridge as Chief Medical Officer, alongside a board that includes co-founder Christoph Westphal and other industry veterans.[4]

Core Differentiators

• Novel Target Selection: The company's focus on CD161 represents a differentiated approach to T cell immunotherapy, targeting a checkpoint that restores activation of both T and NK cells in preclinical models.[2]

• Integrated Discovery Platform: Immunitas combines single-cell genomics for rapid target identification and validation with parallel antibody discovery and engineering, compressing traditional drug development timelines.[2]

• Specialized Scientific Pedigree: The founding team's background from leading cancer research institutions provides deep domain expertise in oncology and immunotherapy development.

• Multi-Indication Pipeline: Beyond its lead oncology program, Immunitas is developing therapeutics for autoimmune diseases, leveraging the same CD161-CLEC2D pathway across multiple disease areas.[1]

Role in the Broader Tech Landscape

Immunitas operates within the broader immuno-oncology and precision medicine movement, where advances in genomics and immunology are enabling the discovery of novel therapeutic targets. The company's use of single-cell genomics reflects the industry-wide trend toward data-driven drug discovery, where high-resolution biological understanding accelerates the identification of clinically relevant targets. This approach aligns with the biotech sector's shift toward mechanism-driven development and away from traditional screening methods.

The timing is favorable for companies targeting immune checkpoints, as the success of checkpoint inhibitors has validated the immunotherapy paradigm while also revealing limitations in existing approaches. Immunitas' focus on CD161 addresses an underexplored mechanism, potentially offering differentiation in a competitive landscape.

Quick Take & Future Outlook

Immunitas stands at a critical inflection point as IMT-009 advances through clinical development. The company's success will depend on demonstrating clinical efficacy in its target indications, particularly in difficult-to-treat cancers like microsatellite-stable colorectal cancer where existing immunotherapies have limited benefit. If IMT-009 shows compelling clinical data, the company could establish CD161 as a validated checkpoint target and expand its pipeline accordingly.

Looking ahead, Immunitas' trajectory will be shaped by clinical trial outcomes, competitive dynamics in immuno-oncology, and the broader biotech funding environment. The company's ability to leverage its genomics platform to identify additional high-value targets will determine whether it becomes a focused single-asset company or a diversified immuno-oncology player. Given the founding team's scientific credibility and the novelty of its target, Immunitas has positioned itself as a meaningful contributor to the next generation of cancer immunotherapy.